British doctors lobby NHS to use cheap Avastin over Lucentis in AMD

Here's a new threat to Lucentis, the eye drug from Roche ($RHHBY) and Novartis ($NVS). British doctors are calling for the National Health Service to routinely use Roche's cancer med Avastin to treat patients with wet age-related macular degeneration, rather than the much costlier Lucentis. The two drugs work in a similar fashion and some studies show they work equally well for eye problems, but Avastin isn't licensed for use in the eye. Report

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Novartis is touting 52-week data for Cosentyx in spondyloarthritis—an indication where Eli Lilly's Taltz recently scored a trailblazing FDA approval.

Bristol Myers Squibb's Zeposia will leverage promising top-line phase 3 data into a possible FDA approval in the lucrative ulcerative colitis market.